Karen Zier, PhD
- PROFESSOR EMERITUS | Medicine, Clinical Immunology
- PROFESSOR EMERITUS | Medical Education
- PROFESSOR EMERITUS | Microbiology
- PROFESSOR EMERITUS | Oncological Sciences
Research Topics:Immunology, T Cells
Multi-Disciplinary Training AreaClinical Research Education Program [CLR]
BA, Hofstra University
PhD, State University of New York
University of Innsbruck
Specific Clinical/Research Interests: Tumor immunology; T cells; immunotherapy and immunosuppression
Summary of Research Studies:
Maintaining established tumor immunity is important to prevent the growth of nascent tumors and to sustain responses induced naturally or by immunotherapy. Although it was thought that the major reason the immune system fails to reject tumors is that they evade detection, more recent evidence has suggested that immune responses made against tumors can be lost before the tumor has been destroyed. Dr. Zier's research interest focuses on regulatory mechanisms that underlie the loss of established anti-tumor immunity. Her lab has shown that as the CMS5 fibrosarcoma grows early anti-tumor immunity wanes. These mice contain T cells that show defects in the TCR signaling pathway. On a functional level, Th1 responses by the T cells decrease, while Th2 responses increase. Most evidence suggests that in contrast to Th2 responses, Th1 responses favor the development of protective immune responses to tumors. Moreover, as tumors grow levels of two types of cells that suppress th! e development of immunity to tumors increase. The first are immature myeloid cells with a Gr1+/CD11b+ phenotype. The second are CD4+/CD25+ T regulatory cells. Current research in the lab is directed at determining the mechanisms responsible for the loss of the protective Th1 response and the development of the deleterious Th2 response, as well as defining the mechanism by which CD4+/CD25+ depletion prevents tumor growth. A particular focus is defining molecules on tumor cells that that may trigger the development of immune suppression. These studies will provide new insights into regulatory mechanisms responsible for the loss of immune responses to solid tumors. This information is crucial to ensure the persistence of natural or therapeutically induced immunity.
Swenson C, Harn D, Zier K. Glycans that induce protective immunity when expressed on schistosome eggs are associated with deleterious responses when expressed on tumor cells. Manuscript submitted.;.
Cohen B, Friedman E, Zier K. Publications by Students Doing A Year of Full-Time Research: What are Realistic Expectations?. Amer J Med 2008; 121: 545.
Zier K, Friedman E, Smith L. Supportive programs increase medical students' research interest and productivity. J. Invest. Med 2006; 54: 201-207.
Bartido SM, Zier K. T-cell responses to multiple antigens presented by RNA-transfected APCs: a possible immunomonitoring tool. Cancer Immunol Immunother 2004 Feb; 53(2): 100-109.
Zier K, Johnson K, Johnson K, Maddux M, Sung M, Mandeli JP, Eisenbach L, Schwartz M. IFNgamma secretion following stimulation with total tumor peptides from autologous human tumors. J Immunol Methods 2000; 241(1-2): 61-68.
Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000 Feb 15; 164(4): 2214-2220.